AU · rank #3 · 2026-10-20
GRAL
NASDAQ · $5.47B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 2.774 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.69 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.193 |
| Analyst upside Consensus target $131.30 | +7.3% |
| Momentum acceleration 3-month minus 12-month momentum. | +64.93% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 3.91 |
| Gross margin TTM | +49.7% |
| 52w high | $166.48 |
| Market cap (USD) | $5.47B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
GRAIL is a healthcare diagnostics company commercializing Galleri, a multi-cancer early-detection blood test capable of identifying cancer signals across more than 50 cancer types.
Rationale
Unanimous analyst target price raises (7 in 30 days) and positive estimate revisions are validated by the favorable September 2026 FDA advisory committee vote for Galleri's PMA approval and a 44.9% quarterly earnings surprise.
Material risks
- 1The FDA could reject or delay final PMA approval or require costly long-term clinical trials demonstrating improved survival outcomes.
- 2Persistent negative gross profit ($12.6M gross loss in Q2) and severe quarterly EBITDA losses (-$90.3M) without broad insurance reimbursement threaten balance sheet sustainability.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.